Edmond DE Rothschild Holding S.A. Cuts Holdings in CVS Health Co. (NYSE:CVS)

Edmond DE Rothschild Holding S.A. cut its holdings in shares of CVS Health Co. (NYSE:CVS - Free Report) by 3.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,132,024 shares of the pharmacy operator's stock after selling 37,659 shares during the quarter. CVS Health accounts for 0.9% of Edmond DE Rothschild Holding S.A.'s holdings, making the stock its 26th largest position. Edmond DE Rothschild Holding S.A. owned 0.09% of CVS Health worth $50,817,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of CVS Health by 3.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 261,194 shares of the pharmacy operator's stock valued at $16,424,000 after purchasing an additional 9,418 shares in the last quarter. Arete Wealth Advisors LLC acquired a new position in CVS Health in the 3rd quarter valued at approximately $1,369,000. Caisse DE Depot ET Placement DU Quebec raised its stake in shares of CVS Health by 4.1% during the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 1,082,145 shares of the pharmacy operator's stock valued at $68,045,000 after acquiring an additional 42,307 shares during the last quarter. Edgestream Partners L.P. lifted its holdings in shares of CVS Health by 7.4% during the third quarter. Edgestream Partners L.P. now owns 20,734 shares of the pharmacy operator's stock worth $1,304,000 after purchasing an additional 1,437 shares during the period. Finally, Cobblestone Capital Advisors LLC NY increased its holdings in CVS Health by 1.5% in the third quarter. Cobblestone Capital Advisors LLC NY now owns 133,848 shares of the pharmacy operator's stock valued at $8,416,000 after purchasing an additional 1,947 shares during the period. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling

In related news, Director Michael F. Mahoney acquired 30,000 shares of the stock in a transaction dated Tuesday, February 18th. The stock was acquired at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the purchase, the director now directly owns 39,356 shares of the company's stock, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP James David Clark sold 7,513 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the transaction, the senior vice president now owns 8,394 shares in the company, valued at $556,941.90. This trade represents a 47.23 % decrease in their position. The disclosure for this sale can be found here. 0.24% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on CVS shares. StockNews.com raised CVS Health from a "sell" rating to a "hold" rating in a report on Thursday, February 13th. Wolfe Research upped their price objective on shares of CVS Health from 67.00 to 70.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Piper Sandler boosted their target price on shares of CVS Health from $72.00 to $74.00 and gave the company an "overweight" rating in a report on Friday, March 21st. Leerink Partners raised CVS Health from a "market perform" rating to an "outperform" rating and lifted their price objective for the stock from $55.00 to $75.00 in a research report on Thursday, February 13th. Finally, Argus set a $77.00 target price on CVS Health in a report on Tuesday, February 18th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, CVS Health currently has a consensus rating of "Moderate Buy" and an average price target of $70.39.

CVS Health Stock Down 3.8 %

CVS stock traded down $2.55 during midday trading on Friday, hitting $64.96. The company's stock had a trading volume of 4,571,555 shares, compared to its average volume of 11,510,031. The company has a market cap of $81.90 billion, a PE ratio of 17.72, a P/E/G ratio of 0.98 and a beta of 0.54. The firm's 50-day moving average is $63.29 and its 200-day moving average is $57.97. CVS Health Co. has a 12 month low of $43.56 and a 12 month high of $75.27. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. On average, equities research analysts forecast that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd will be issued a $0.665 dividend. The ex-dividend date of this dividend is Tuesday, April 22nd. This represents a $2.66 annualized dividend and a dividend yield of 4.09%. CVS Health's dividend payout ratio (DPR) is 72.68%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.